Erlocip 150 mg contains erlotinib, a targeted cancer therapy used primarily in the treatment of certain types of lung and pancreatic cancers. Unlike traditional chemotherapy, erlotinib works by specifically blocking signals that cancer cells need to grow and divide. It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs) and offers a more focused approach to treatment, especially in patients whose tumors have specific genetic characteristics. Erlocip is taken orally, offering convenience for patients undergoing long-term treatment.

Mechanism of Action

Erlotinib works by inhibiting the epidermal growth factor receptor (EGFR), a protein found on the surface of both normal and cancer cells. In many cancers, EGFR is overactive or mutated, which promotes rapid cell division and tumor growth. By blocking the activity of this receptor, erlotinib slows down or stops the growth of cancer cells. Its effects are most pronounced in tumors with EGFR mutations, making genetic testing an important part of treatment planning.

Uses

Erlocip is mainly prescribed for:

• Non-small cell lung cancer (NSCLC), especially in patients with EGFR mutations

• Pancreatic cancer, in combination with another chemotherapy drug (gemcitabine)

• It may be considered in other cancers off-label based on oncologist discretion and genetic profiling

  Adverse Effects

  Common side effects

  • Skin rash resembling acne, usually on the face and upper body

  • Diarrhea

  • Loss of appetite

  • Fatigue

  • Dry skin or itching

  • Mouth sores